Business / Finance

RSS

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

ESSA Pharma Inc. is pleased to announce that it has received final approval for its common shares to be listed and commence trading on the Toronto Stock Exchange.

28 Jul 2015

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.

28 Jul 2015

Genesis files shelf registration statement with the U.S. Securities and Exchange Commission

Genesis HealthCare, one of the nation's largest providers of post-acute care, today announced that it has filed a shelf registration statement on Form S-3 with the United States Securities and Exchange Commission.

25 Jul 2015

Girls are born with weaker spines compared to boys, study finds

Looking at measurements of the vertebrae - the series of small bones that make up the spinal column - in newborn children, investigators at Children's Hospital Los Angeles found that differences between the sexes are present at birth. Results of the study, now online in advance of publication in the August issue of the Journal of Pediatrics, suggest that this difference is evolutionary, allowing the female spine to adapt to the fetal load during pregnancy.

25 Jul 2015

Lupin signs strategic asset purchase agreement with Temmler

Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.

25 Jul 2015

TSO3 obtains purchase orders from the US for STERIZONE sterilization system

TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has received purchase orders for multiple devices from the US. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and the Company.

24 Jul 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

The Gladstone Institutes announces the creation of Cure Network Ventures Inc. and Cure Network Dolby Acceleration Partners, LLC, a business endeavor with Dolby Family Ventures and Evotec AG, which will focus on Alzheimer's disease. Working through Cure Network Ventures, Inc., the new company will help expedite the translation of relevant scientific discoveries from the Gladstone Institute of Neurological Disease into the development of potential therapies.

24 Jul 2015

NeoGraft selects Verasoni Worldwide as marketing communications partner

NeoGraft is pleased to announce the selection of Verasoni Worldwide as integrated marketing communications partner. NeoGraft is a world leader in hair replacement technology serving physicians and patients in the United States and around the world. NeoGraft is the first Class One FDA Listed automated medical device for hair restoration.

23 Jul 2015

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).

23 Jul 2015

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively.

23 Jul 2015

Lupin enters into definitive agreement to acquire GAVIS

Pharma Major Lupin Limited has entered into a definitive agreement to acquire privately held GAVIS Pharmaceuticals LLC and Novel Laboratories Inc., subject to certain closing conditions, in a transaction valued at USD 880 million, cash free and debt free.

23 Jul 2015

ADPT generates systemwide net patient services revenue of $104.5 million for Q2 2015

Adeptus Health Inc., the largest operator of freestanding emergency rooms in the U.S., announced its results for the second quarter ended June 30, 2015.

23 Jul 2015

NeoGenomics' revenue increases 18% to $24.3 million in second quarter 2015

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2015.

23 Jul 2015

Quest Diagnostics' second quarter revenue grows by 1.2% to $1.93 billion

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that for the second quarter ended June 30, 2015, adjusted net income was $170 million compared to $157 million for 2014. Adjusted diluted EPS excluding amortization was $1.25 in the second quarter of 2015, compared to $1.19 in 2014. Amortization expense per diluted share was $0.08 in the second quarter of 2015 and $0.11 in 2014.

From Quest Diagnostics 23 Jul 2015

Danaher's revenue for second quarter 2015 increases 3.5% to $5.1 billion

Danaher Corporation today announced record results for the second quarter 2015. For the quarter ended July 3, 2015, non-GAAP adjusted diluted net earnings per share were $1.08, which reflects the adjustments identified in the attached reconciliation schedule. On a GAAP basis, diluted net earnings for the second quarter were $696 million, or $0.97 per share. Revenue for the second quarter 2015 increased 3.5% to $5.1 billion with core revenues also increasing 3.5%.

23 Jul 2015

Veeva OpenData services now available in Italy

Today, Veeva Systems announced that it has acquired Merqurio's healthcare professional (HCP) and healthcare organisation (HCO) database for Italy. With the acquisition of this market-leading Italian HCP and stakeholder data, Veeva OpenData now expands to a third major European market and builds on Veeva's commitment to deliver a new approach to customer reference data that is open, easy, and global.

23 Jul 2015

Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

Enigma Diagnostics Ltd. and Beijing Leadman Biochemistry Co., Ltd. signed a joint venture agreement with the principal goal of delivering the Enigma MiniLab molecular diagnostic Point-of-Care platform into the Chinese health care market to support its growing diagnostic needs.

23 Jul 2015

MediCollector to commercialize Wyss Institute's bedside data-acquisition software

The Wyss Institute for Biologically Inspired Engineering at Harvard University today announced that its bedside data-acquisition software will be commercialized by a recently formed startup company, MediCollector LLC. The announcement follows a worldwide license agreement between Harvard's Office of Technology Development and MediCollector.

23 Jul 2015

Perrigo signs agreement to acquire Naturwohl Pharma

Perrigo Company plc today announced that it has entered into an agreement to acquire Naturwohl Pharma GmbH with its leading German dietary supplement brand, Yokebe. The brand is expected to generate approximately €30 million in full year 2015 net sales.

22 Jul 2015

Business / Finance

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Genesis files shelf registration statement with the U.S. Securities and Exchange Commission

Girls are born with weaker spines compared to boys, study finds

Lupin signs strategic asset purchase agreement with Temmler

TSO3 obtains purchase orders from the US for STERIZONE sterilization system

3SBio purchases entire equity interest in Zhejiang Wansheng

Gladstone Institutes announces new business endeavor with Evotec and Dolby Family Ventures

NeoGraft selects Verasoni Worldwide as marketing communications partner

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

SutroVax completes $22 million Series A financing

Lupin enters into definitive agreement to acquire GAVIS

ADPT generates systemwide net patient services revenue of $104.5 million for Q2 2015

NeoGenomics' revenue increases 18% to $24.3 million in second quarter 2015

Quest Diagnostics' second quarter revenue grows by 1.2% to $1.93 billion

Danaher's revenue for second quarter 2015 increases 3.5% to $5.1 billion

Veeva OpenData services now available in Italy

Enigma, Beijing Leadman sign agreement for MiniLab molecular diagnostic Point-of-Care platform

MediCollector to commercialize Wyss Institute's bedside data-acquisition software

Perrigo signs agreement to acquire Naturwohl Pharma

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News